"GlycoVision results featured at ESMO 2024: read the interview here to learn how InterVenn is powering new prognostic and predictive biomarkers!

Your partner for clinical glycoproteomics

We’ve developed the GlycoVision™ platform to exponentially improve the speed, scope, and scale of glycoproteomic analysis - enabling new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring.

A new era of precision medicine is here.

Discover GlycoVision

High-resolution glycoproteomics

At InterVenn Biosciences, we’ve built our proprietary platform to unlock the glycoproteome with unparalleled detail, pioneering this untapped layer of biology on a clinically meaningful scale.

Glycosylation of proteins controls the activation state of immune cells and can distinguish specific physiological states. By exploring how proteins are glycosylated and how these modifications affect protein function, we can uncover invaluable insights into the molecular mechanisms underlying health and disease.

Learn About Glycoproteomics

Who We Are

We are a life sciences company founded on the belief that no one should ever be blindsided by disease. We aim to expand the -omics universe by harnessing the power of the glycoproteome - ushering in a new era of personalized, predictive, and preventive care.

Clinical Evidence

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Journal of Hematology & Oncology | March 22, 2024

Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling

Gastroenterology | September 25, 2023

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

Frontier in Immunology | June 13, 2023

Get in touch